Edition:
United States

XBiotech Inc (XBIT.OQ)

XBIT.OQ on NASDAQ Stock Exchange Global Select Market

4.20USD
14 Aug 2018
Change (% chg)

$-0.10 (-2.33%)
Prev Close
$4.30
Open
$4.27
Day's High
$4.27
Day's Low
$4.20
Volume
3,182
Avg. Vol
30,655
52-wk High
$5.80
52-wk Low
$3.70

Chart for

About

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also... (more)
No analyst recommendations are available for .

Overall

Beta: 0.66
Market Cap(Mil.): $147.41
Shares Outstanding(Mil.): 35.52
Dividend: --
Yield (%): --

Financials

  XBIT.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -0.68 -- --
ROI: -37.57 1.42 12.88
ROE: -37.58 0.52 15.04

BRIEF-XBiotech Announces First Patient In Phase 2 Study Evaluating Patients With Atopic Dermatitis

* XBIOTECH ANNOUNCES FIRST PATIENT IN PHASE 2 STUDY EVALUATING MABP1 IN PATIENTS WITH ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

Apr 16 2018

BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

Apr 16 2018

BRIEF-XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer

* HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG Source text for Eikon: Further company coverage:

Apr 02 2018

Earnings vs. Estimates